Janssen, GSK China HIV Approvals Show Increased Transparency
This article was originally published in The Pink Sheet Daily
In a rare move and further indication of a determination to break away from its past, China FDA has made timely public announcements of the approval of two new treatments for HIV that it deems to be breakthroughs, although it could be some time before they reach the market.
You may also be interested in...
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.